Anzeige
Mehr »
Dienstag, 23.09.2025 - Börsentäglich über 12.000 News
Der nächste große KI-Durchbruch in der Frauengesundheit?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0MS6X | ISIN: US6024961012 | Ticker-Symbol: N/A
NASDAQ
22.09.25 | 21:59
7,170 US-Dollar
+2,14 % +0,150
1-Jahres-Chart
MIMEDX GROUP INC Chart 1 Jahr
5-Tage-Chart
MIMEDX GROUP INC 5-Tage-Chart
GlobeNewswire (Europe)
140 Leser
Artikel bewerten:
(0)

MiMedx Group, Inc: MIMEDX Announces Strategic Collaboration with Vaporox, Inc.

MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") and Vaporox, Inc. ("Vaporox") today jointly announced a collaboration, whereby the companies will co-promote and co-market their wound care offerings. As part of the agreement, MIMEDX has made an investment in Vaporox and the Company has certain exclusivity rights related to potential acquisition discussions.

Vaporox is a privately held, Denver-based company that has developed and is commercializing its patented Vaporous Hyperoxia Therapy ("VHT") device for treating chronic and hard-to-heal wounds. VHT delivers two healing modalities, ultrasonic mist and concentrated oxygen, in a single device and has received a 510(k) clearance from the U.S. Food & Drug Administration ("FDA") to treat nine types of wounds, including Diabetic Foot Ulcers ("DFUs"), Venous Leg Ulcers ("VLUs") and Pressure Ulcers (bed sores).

"We are thrilled to continue delivering on our strategic goal of greater portfolio diversification through this collaboration with Vaporox," commented Joseph H. Capper, MIMEDX Chief Executive Officer. "Together with our leading placental allografts, VHT will offer clinicians across numerous care settings another proven option to treat chronic, hard-to-heal wounds. We view this as a highly complementary addition that will help us grow in this important setting, where patients with difficult wounds often begin their recovery."

"Vaporox is excited to partner with a market leader in wound care to expand awareness and adoption of our technology," said Alan Sage, Chief Executive Officer of Vaporox. "We believe co-promotion with MIMEDX will accelerate our market penetration and create a synergistic offering-allowing us to reach more patients with these highly complementary offerings."

VHT has been the subject of three IRB clinical studies, each of which demonstrated wound healing rates exceeding 80% at 20 weeks when combined with standard wound care. Additionally, Vaporox's VHT is an adjunct therapy that has shown promising signs of efficacy in real-world use cases with MIMEDX's Advanced Wound Care products, such as EPIFIX®.

About Vaporox, Inc.
Vaporox's technology represents a breakthrough in treating chronic wounds. The company is focused on superior healing outcomes while reducing costs across a wide range of healthcare settings. With strong clinical results and growing adoption, Vaporox empowers providers to restore hope and healing for patients suffering from chronic wounds.

For additional information, please visit https://www.vaporox.com/.

About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company's vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com


© 2025 GlobeNewswire (Europe)
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.